Peter Loftus on Muck Rack

Peter Loftus Verified

Wall Street Journal @WSJ reporter covering pharmaceutical industry. Contact me at 215-881-7127, peter.loftus@wsj.com.

FDA Says Certain Type 2 Diabetes Drugs Can Cause Serious Joint Pain

wsj.com — The FDA said patients should contact their doctors if they experience severe and persistent joint pain The U.S. Food and Drug Administration said in a safety alert Friday some widely used treatments for Type 2 diabetes can cause severe and disabling joint pain, raising concerns for a big-selling class of drugs.
Aug 28, 2015

FDA says certain Type 2 diabetes drugs can cause serious joint pain. on.wsj.com/1WXnoLZ via @WSJ @loftus $MRK $AZN $LLY

Aug 28, 2015

RT @JeanneWhalen: FDA says certain Type 2 diabetes drugs can cause serious joint pain. on.wsj.com/1WXnoLZ via @WSJ @loftus $MRK $AZN $LLY

Aug 28, 2015

RT @WSJ: FDA: Some widely used treatments for Type 2 diabetes can cause severe and disabling joint pain. on.wsj.com/1UizRFO

Aug 28, 2015

RT @JeanneWhalen: FDA says certain Type 2 diabetes drugs can cause serious joint pain. on.wsj.com/1WXnoLZ via @WSJ @loftus $MRK $AZN $LLY

Aug 30, 2015

RT @WSJ: FDA: Some widely used treatments for Type 2 diabetes can cause severe and disabling joint pain. on.wsj.com/1NPTTIa

Show 1 more tweet from Monica Nino

Unapproved Lilly Lung Cancer Drug Stirs Price Debate

wsj.com — An experimental Eli Lilly & Co. lung cancer drug hasn't reached the market, but some doctors are already weighing in on how much it should cost-arguing the price should be below average because the drug extended patient lives by only six to seven weeks in a clinical trial.
Aug 27, 2015

$LLY cancer drug hasn't yet reached the market, but docs are already publishing views on what it should cost on.wsj.com/1WUCVw9 @loftus

Aug 27, 2015

RT @JeanneWhalen: $LLY cancer drug hasn't yet reached the market, but docs are already publishing views on what it should cost on.wsj.com/1WUCVw9 @loftus

Aug 27, 2015

Unapproved Lilly Lung Cancer Drug Stirs Price Debate on.wsj.com/1WUCVw9 via @WSJ $LLY

Aug 27, 2015

RT @Loftus: Unapproved Lilly Lung Cancer Drug Stirs Price Debate on.wsj.com/1WUCVw9 via @WSJ $LLY

Aug 27, 2015

Emory docs say $LLY cancer drug should cost $1,745/month based on benefit. Most new cancer drugs cost > $10,000/mo. on.wsj.com/1WUCVw9

Show 8 more tweets from Meg Tirrell, Stefanie Ilgenfritz and others...

In See-Something-Say-Something Era, Geocachers’ Hidden Treasures Set Off Alarms

wsj.com — DOVER, Del.-A groundskeeper at a popular park here recently found a suspicious package stuck to the side of a large electrical box, just yards from a building where dozens of youngsters were about to play basketball. Alarmed, the groundskeeper called the police, who mustered a bomb squad.
Aug 21, 2015

(Ahed) In 'see something say something' era, geocachers’ hidden treasures set off alarms on.wsj.com/1h1NuMX via @Loftus @WSJ

Aug 21, 2015

In see-something-say-something era, geocachers’ hidden treasures set off alarms on.wsj.com/1h1NuMX via @WSJ

Aug 21, 2015

One Man’s Hidden Treasure Is Another Man’s Bomb Scare via @Loftus wsj.com/articles/in-se…

Aug 21, 2015

RT @BrianHershberg: In see-something-say-something era, geocachers’ hidden treasures set off alarms | on.wsj.com/1h1NuMX pic.twitter.com/hz8JbjOZil

Aug 21, 2015

In see-something-say-something era, geocachers’ hidden treasures set off alarms | on.wsj.com/1h1NuMX pic.twitter.com/hz8JbjOZil

Show 10 more tweets from Peter Loftus, Peter Loftus and others...

Drug-Plan Managers Wield ‘Potent Weapon’

wsj.com — CVS Health Corp.'s decision to stop covering Pfizer Inc.'s anti-impotence pill Viagra for many of its drug-benefit plan members is the latest example of the tough tactics some health-care managers are using to control rising drug costs. CVS and rival Express Scripts Holding Co., which together dominate the U.S.
Aug 06, 2015

Drug-Plan managers wield ‘potent weapon’; CVS excludes Viagra from preferred list: on.wsj.com/1IpjcwU via @WSJ

Aug 06, 2015

RT @Loftus: Drug-Plan managers wield ‘potent weapon’; CVS excludes Viagra from preferred list: on.wsj.com/1IpjcwU via @WSJ

Aug 07, 2015

PBMs getting tougher, dropping more drugs from formulary instead of just putting them in higher tier.’ on.wsj.com/1IpjcwU via @Loftus

Aug 07, 2015

RT @Loftus: Drug-Plan managers wield ‘potent weapon’; CVS excludes Viagra from preferred list: on.wsj.com/1IpjcwU via @WSJ

Aug 07, 2015

Companies than manage U.S. pharmaceutical benefits are increasingly dropping coverage of some drugs to control costs on.wsj.com/1IpjcwU

Show 3 more tweets from Jeanne Whalen, Laura Landro and others...

WHO Says Ebola Vaccine Effective in African Trial

wsj.com — European researchers said Friday that an experimental Ebola vaccine tested in Guinea "might be effective" in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink Genetics Corp.
Jul 31, 2015

WHO Says Ebola Vaccine Effective in African Trial; controversy lingers on.wsj.com/1Iu4dyG My story via @WSJ

Jul 31, 2015

WHO Says Ebola Vaccine Effective in African Trial; controversy over trial protocol on.wsj.com/1Iu4dyG My story with @Loftus on @WSJ

Jul 31, 2015

WHO says Ebola vaccine 100% effective; debate continues. My @WSJ story w @Loftus wsj.com/articles/who-s… Getty Images pic.twitter.com/Ggj1nZS5i8

Show 11 more tweets from Stefanie Ilgenfritz, Andrew Seaman and others...

Merck Earnings Hurt by Arthritis Drug Knockoffs

wsj.com — Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second quarter, hurt by currency changes and recent divestitures.
Jul 28, 2015

Merck earnings hurt by knockoffs of arthritis drug Remicade in Europe: on.wsj.com/1IoKAIg via @WSJ $MRK

Jul 28, 2015

Biosimilars are already starting to bite at Merck, where 2Q earnings were hurt by biosimilar Remicade. on.wsj.com/1IoKAIg by @loftus

Jul 28, 2015

RT @JeanneWhalen: Biosimilars are already starting to bite at Merck, where 2Q earnings were hurt by biosimilar Remicade. on.wsj.com/1IoKAIg by @loftus

Jul 29, 2015

Remicade knockoffs, priced 45% below branded drug, hurt Merck earnings on.wsj.com/1IoKAIg

Jul 29, 2015

RT @helenwsj: Remicade knockoffs, priced 45% below branded drug, hurt Merck earnings on.wsj.com/1IoKAIg

Lilly’s Alzheimer’s drug may slow patients’ decline, study shows

marketwatch.com — WASHINGTON-People with mild Alzheimer's disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial. The outcome may bolster the case among investors that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer's patients, despite prior studies with negative results.

Lilly’s Alzheimer’s Drug May Slow Patients’ Decline, Study Shows

wsj.com — Separate study shows experimental Biogen drug also holds promise WASHINGTON-People with mild Alzheimer's disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.
Jul 22, 2015

Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Jul 22, 2015

RT @Loftus: Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Jul 22, 2015

RT @ShirleyWang: Lilly’s Alzheimer’s drug may slow patients’ decline, study shows on.wsj.com/1Jxlw2Q via @WSJ

Jul 22, 2015

RT @Loftus: Lilly’s Alzheimer’s drug may slow patients’ decline, study suggests on.wsj.com/1Jxlw2Q via @WSJ $LLY $BIIB #AAIC2015

Show 3 more tweets from Stefanie Ilgenfritz, Peter Loftus and others...

Rising U.S. Drug Prices Are Focus of Research Grant

wsj.com — A Houston philanthropist couple plans to announce Tuesday that they are providing a $5.2 million grant to a Boston nonprofit, the Institute of Clinical and Economic Review, to expand the group's research evaluating whether new drugs are worth their price tags. ICER research has already made a mark: Some U.S.
Jul 21, 2015

More focus on whether drugs offer V for M. Rising U.S. drug prices are focus of research grant on.wsj.com/1Ml7irJ via @WSJ

Jul 21, 2015

Rising U.S. drug prices are focus of $5M research grant from Arnold Foundation: on.wsj.com/1Ml7irJ via @WSJ

Show 8 more tweets from Rob Weisman, Stefanie Ilgenfritz and others...

Alzheimer’s Drug Is a Big Bet for Lilly

wsj.com — Researchers will provide clues about whether Eli Lilly & Co.'s risky bet on an experimental drug for Alzheimer's disease ultimately pays off-for patients and for Lilly's bottom line. Scientists are scheduled to present results from a clinical trial of the drug, solanezumab, at the Alzheimer's Association International Conference in Washington.
Jul 19, 2015

Key test for #Alzheimers drug candidate solanezumab--and $LLY--when data in mild patients is released Wed on.wsj.com/1LtaZKo by @Loftus

Jul 19, 2015

Researchers will provide clues this week about whether Lilly’s bet on an Alzheimer’s drug pays off on.wsj.com/1LtaZKo via @WSJ $LLY

Jul 20, 2015

Big test for Eli Lilly as it is set to release results on its new Alzheimer’s drug: on.wsj.com/1MjYOkP

Jul 20, 2015

Researchers will provide clues about whether Lilly’s bet on an Alzheimer’s drug pays off on.wsj.com/1LtaZKo via @WSJ

Jul 20, 2015

New Alzheimer's data from Lilly this week will help show whether there's any fight left in amyloid hypothesis on.wsj.com/1LtaZKo @loftus

More Articles →
Aug 28, 2015

RT @JeanneWhalen: FDA says certain Type 2 diabetes drugs can cause serious joint pain. on.wsj.com/1WXnoLZ via @WSJ @loftus $MRK $AZN $LLY

Aug 28, 2015

Darryl Dawkins on breaking the backboard: 'I hit it with the force of a thousand strong men, a thousand strong men': philly.com/philly/sports/…

Aug 27, 2015

RT @jonathanrockoff: $AMGN's Repatha PCSK9 drug gets @US_FDA approval. Its indication, from news release, is below. $SNY $REGN pic.twitter.com/ldbCVR5pBD

Aug 27, 2015

MacGyver's entry seems overdue, but maybe it just took him awhile to construct it out of dried leaves twitter.com/WSJ/status/636…

Aug 27, 2015

RT @jonathanrockoff: $AMGN confirms: It has asked federal appellate court to enjoin $NVS from selling Neupogen #biosimilar Zarxio pending decision on re-hearing

Aug 27, 2015

Unapproved Lilly Lung Cancer Drug Stirs Price Debate on.wsj.com/1WUCVw9 via @WSJ $LLY

Aug 26, 2015

Pope Francis memorabilia ahead of visit to Philadelphia includes 'Holy Wooder' craft beer: on.wsj.com/1Iee6QO via @WSJ @scottmcalvert

Aug 25, 2015

Debate over a new way to treat early-stage breast cancer with a single dose of radiation on.wsj.com/1hDeBim via @WSJ @melindabeckwsj


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.